Novartis AG $NVS Shares Sold by Dillon & Associates Inc.

Dillon & Associates Inc. trimmed its position in Novartis AG (NYSE:NVS) by 25.6% in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 2,277 shares of the company’s stock after selling 784 shares during the period. Dillon & Associates Inc.’s holdings in Novartis were worth $276,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors also recently bought and sold shares of NVS. Essex Savings Bank lifted its stake in shares of Novartis by 1.9% during the second quarter. Essex Savings Bank now owns 4,611 shares of the company’s stock worth $558,000 after buying an additional 85 shares during the period. Physician Wealth Advisors Inc. lifted its stake in shares of Novartis by 5.8% during the second quarter. Physician Wealth Advisors Inc. now owns 1,541 shares of the company’s stock worth $186,000 after buying an additional 85 shares during the period. Deroy & Devereaux Private Investment Counsel Inc. lifted its stake in shares of Novartis by 4.4% during the second quarter. Deroy & Devereaux Private Investment Counsel Inc. now owns 2,062 shares of the company’s stock worth $250,000 after buying an additional 87 shares during the period. Forum Financial Management LP lifted its stake in shares of Novartis by 0.4% during the second quarter. Forum Financial Management LP now owns 24,607 shares of the company’s stock worth $2,978,000 after buying an additional 88 shares during the period. Finally, Avidian Wealth Enterprises LLC lifted its stake in shares of Novartis by 1.2% during the second quarter. Avidian Wealth Enterprises LLC now owns 7,749 shares of the company’s stock worth $938,000 after buying an additional 90 shares during the period. 13.12% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research analysts recently issued reports on the stock. HC Wainwright cut shares of Novartis to a “neutral” rating in a report on Monday, October 27th. Wall Street Zen cut shares of Novartis from a “strong-buy” rating to a “hold” rating in a report on Saturday. Jefferies Financial Group reaffirmed a “hold” rating on shares of Novartis in a report on Monday, October 27th. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating on shares of Novartis in a report on Thursday, August 21st. Finally, Cfra Research raised shares of Novartis to a “hold” rating in a report on Wednesday, October 29th. One research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, six have given a Hold rating and three have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $122.33.

Novartis Stock Up 0.1%

NVS stock opened at $123.97 on Tuesday. The stock has a market capitalization of $261.88 billion, a P/E ratio of 16.94, a P/E/G ratio of 1.93 and a beta of 0.64. The firm has a 50-day simple moving average of $127.35 and a 200-day simple moving average of $120.37. The company has a quick ratio of 0.62, a current ratio of 0.88 and a debt-to-equity ratio of 0.50. Novartis AG has a 52 week low of $96.06 and a 52 week high of $133.55.

Novartis (NYSE:NVS) last released its earnings results on Tuesday, October 28th. The company reported $2.25 EPS for the quarter, missing analysts’ consensus estimates of $2.26 by ($0.01). The company had revenue of $13.91 billion for the quarter, compared to analysts’ expectations of $13.70 billion. Novartis had a return on equity of 41.21% and a net margin of 26.49%.The firm’s revenue for the quarter was up 8.5% on a year-over-year basis. During the same period in the prior year, the firm earned $2.06 EPS. Equities analysts forecast that Novartis AG will post 8.45 earnings per share for the current fiscal year.

Novartis Company Profile

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.